top of page
Search

Site Initiation Visit (SIV): A Complete Checklist for Clinical Trial Sites

3 hours ago
7 min read

Key Takeaways


  • A site initiation visit (SIV) prepares clinical trial sites for study-specific activities before participant enrollment.

  • The principal investigator and research team must understand the protocol, GCP requirements, and assigned responsibilities.

  • Essential documents, staff training, facilities, and equipment should be ready before the visit.

  • The SIV covers informed consent, participant safety, investigational products, and data management.

  • A structured SIV checklist helps identify gaps and organize site preparation.

  • Participant enrollment can begin only after required site activation authorization is received.


Quick Answer

A site initiation visit (SIV) is a study-specific meeting conducted by a sponsor or Contract Research Organization (CRO) to prepare a selected clinical trial site before participant enrollment. An SIV checklist helps research sites verify staff training, documentation, facilities, and operational readiness; identify outstanding requirements; and address gaps before receiving authorization to activate the site.


Introduction


A clinical trial site may have a qualified investigator, experienced staff, and suitable facilities. However, these resources alone do not mean the site is ready to begin a study.


The research team must understand the protocol, know its responsibilities, and have the necessary documentation and operational processes in place.


This is where a site initiation visit (SIV) becomes important.


For new and research-naive sites, preparation can feel overwhelming. There may be unfamiliar documents, multiple departments to coordinate, and several study-specific procedures to understand.


A structured checklist helps simplify this process. It gives the team a clear way to review requirements, identify gaps, and prepare for the sponsor's expectations.


What Is a Site Initiation Visit in Clinical Research?


A site initiation visit (SIV) is a study-specific meeting conducted by a sponsor or CRO, usually through an assigned CRA. It takes place after a site has been selected and during the final stages of study preparation, before participant enrollment.


The purpose is to ensure that the principal investigator (PI) and research team understand how to conduct the study according to the approved protocol, applicable regulations, and Good Clinical Practice (GCP).


  • An SIV typically covers:

  • Protocol requirements and study procedures.

  • Investigator and staff responsibilities.

  • Regulatory and essential documentation.

  • Informed consent procedures.

  • Participant safety and adverse event reporting.

  • Investigational product handling.

  • Data collection and documentation.


An SIV is part of the broader clinical study start-up process. It helps confirm that the selected site can move from preparation to study conduct.


How to Prepare for a Site Initiation Visit: Complete Checklist


Knowing how to prepare for a site initiation visit starts with understanding the protocol and reviewing the sponsor's document request list.


Use this site initiation visit checklist to organize the team's preparation.


1. Regulatory Documents and Investigator Site File


Start by reviewing the essential study documentation.


  • Current approved protocol and amendments.

  • Applicable IRB/IEC approval letters.

  • Approved informed consent forms.

  • Current Investigator's Brochure, where applicable.

  • PI and sub-investigator CVs and professional credentials.

  • Financial disclosure documentation, where applicable.

  • Investigator agreements and FDA Form 1572, when required.

  • Laboratory certifications and reference ranges, where applicable.


Organize the investigator site file (ISF), so documents are accessible, current, and appropriately signed.


2. Staff Qualifications and Training


The research team must understand the study activities assigned to them.


Check that:


  • Relevant personnel have completed applicable GCP training.

  • The PI and staff have reviewed the current protocol.

  • Study-specific training is documented.

  • The Delegation of Authority Log reflects assigned responsibilities.

  • Staff understand informed consent and safety reporting procedures.

  • Training records are available for review.


The PI should confirm that delegated personnel are qualified for their assigned activities.


3. Facilities and Equipment


Review whether the site can perform the procedures required by the protocol.


  • Examination and consultation rooms are available.

  • Participant records can be stored securely.

  • Required medical and laboratory equipment is available.

  • Equipment calibration and maintenance records are current, where applicable.

  • Refrigerators and freezers meet required storage conditions.

  • Emergency equipment is available when required.


4. Investigational Product and Pharmacy Readiness


For studies involving investigational products (IP), review:


  • Required storage conditions.

  • Temperature monitoring procedures.

  • Product receipt and accountability records.

  • Authorized dispensing personnel.

  • Randomization and blinding procedures, where applicable.

  • Product return and disposal instructions.


5. Informed Consent and Participant Safety


The team should understand how to obtain and document informed consent before trial participation.


Review:


  • Current approved consent forms.

  • Personnel authorized to conduct consent discussions.

  • Consent documentation and filing procedures.

  • Adverse event (AE) and serious adverse event (SAE) reporting.

  • Sponsor and emergency contact information.

  • Protocol-specific safety and escalation procedures.


6. Data Management and Study Systems


Confirm that the research team can manage study information correctly.


  • Electronic Data Capture (EDC) accounts and appropriate access.

  • Source document templates and worksheets.

  • Case Report Form (CRF/eCRF) completion procedures.

  • Data entry timelines.

  • Query management processes.

  • Source record access for monitoring.

  • Study-specific communication and reporting procedures.


Note: This is a general SIV checklist, not a universal list of mandatory documents. The study protocol, sponsor requirements, institution, and applicable regulations determine the final requirements. ICH E6(R3) provides the current international GCP framework for investigator responsibilities, essential records, and trial oversight.



What Happens During a Site Initiation Meeting?


Once the preparation work is underway, the CRA or sponsor representative conducts the Site Initiation Meeting.


A typical agenda includes:


  1. Study introduction: Review the trial objectives, design, and expectations.

  2. Protocol training: Discuss eligibility criteria, visit schedules, and study procedures.

  3. Informed consent: Explain the approved consent process and documentation.

  4. Safety reporting: Review adverse event reporting and emergency procedures.

  5. Investigational product: Explain storage, dispensing, and accountability.

  6. Data management: Discuss source documentation, CRFs, and EDC systems.

  7. Questions and action items: Address concerns and document outstanding requirements.


The CRA records meeting attendance, training, and relevant follow-up items. Staff should ask questions whenever a procedure or responsibility is unclear.


What Happens After the Site Initiation Visit?


The work does not end when the meeting finishes.


The CRA typically prepares an SIV report and communicates outstanding requirements to the research team.


The site should then:


  • Review the SIV report and action items.

  • Submit missing or corrected documentation.

  • Complete outstanding staff training.

  • Resolve equipment, supply, or system-access gaps.

  • Confirm required approvals and agreements.

  • Obtain the sponsor's required site activation authorization.


Completing an SIV does not automatically authorize participant enrollment. The site must satisfy the applicable activation requirements and receive the required authorization before enrollment begins.


How Is an SIV Different From Other Site Visits?


Each visit serves a different purpose during clinical trial preparation.

Visit  

Primary purpose  

Typical timing  

Site Feasibility Assessment  

Evaluates potential site capabilities and resources  

Early planning  

Site Qualification Visit (SQV)  

Assesses whether a potential site can conduct the proposed study  

During site selection  

Site Initiation Visit (SIV)  

Provides study-specific training and reviews site readiness  

Before enrollment  

Monitoring Visit  

Reviews ongoing study conduct, participant safety and data quality  

During the trial  

These activities are connected, but each answers a different question during site preparation. Clinical trial site selection identifies sites that may be suitable for a study.


As part of this process, site feasibility in clinical trials helps determine whether a site has the patient population, staff, facilities, and resources needed to meet the protocol's requirements.


For sites that remain under consideration, site qualification visits (SQV) allow the sponsor or CRO to assess their capabilities in greater detail. Once a site is selected, the SIV shifts the focus from evaluating suitability to preparing the research team to conduct the study.


Who Should Attend a Site Initiation Visit?


The attendees depend on the study design and the procedures involved. However, the following individuals commonly participate:


  • Principal Investigator (PI): Provides medical oversight and understands the investigator's responsibilities.

  • Sub-investigators: Review delegated clinical activities and study procedures.

  • Clinical Research Coordinator (CRC): Coordinates daily study activities, documentation, and participant visits.

  • Clinical Research Associate (CRA): Conducts protocol training and reviews study-specific readiness.

  • Research nurses: Review participant assessments and clinical procedures.

  • Pharmacy personnel: Understand investigational product storage, dispensing, and accountability.

  • Laboratory staff: Review specimen collection, processing, storage, and shipment procedures.

The PI should ensure that all delegated staff receive training appropriate to their responsibilities.


How CSRS Helps Clinical Research Sites Build Readiness


Preparing for an SIV requires more than organizing documents. Research teams also need the knowledge, operational systems, and practical guidance to conduct clinical trials according to study requirements.


Clinical Science Research Solutions (CSRS) supports this process through clinical research education, mentorship, and site development services, particularly for underserved and research-naive communities.


For individuals new to the industry, the CSRS Research Naive Institute Course provides foundational clinical research education, helping aspiring professionals understand clinical trial operations and their potential responsibilities.


For healthcare professionals and emerging site owners, the Site Ownership Program offers guidance on developing compliant workflows, SOPs, quality documentation, and sponsor-ready operations. As a clinical research center in southeast Missouri, CSRS is also committed to strengthening research infrastructure and expanding access to clinical trial opportunities.


Through education and practical site development support, CSRS helps research professionals and emerging sites develop the knowledge and operational foundations needed to participate in clinical trials.


Conclusion


A successful site initiation visit (SIV) depends on more than completing paperwork. It requires a prepared research team, organized documentation, suitable facilities, and a clear understanding of study responsibilities.


Using a structured SIV checklist helps research sites identify gaps, prepare staff, and address outstanding requirements before activation.


For new and established sites alike, strong preparation creates a better foundation for conducting clinical trials responsibly.


Frequently Asked Questions


How long does a site initiation visit (SIV) take?

A site qualification visit assesses whether a research site has the qualified staff, facilities, equipment, and operational resources needed to conduct a specific clinical trial.

An SIV or equivalent documented initiation process is generally part of sponsor-led site preparation. The site must also meet applicable activation requirements before enrolling participants.

Yes. Sponsors may conduct remote or hybrid SIVs when appropriate. The format depends on the study requirements and sponsor's monitoring plan.

The CRA documents outstanding requirements and communicates follow-up actions. The site must resolve applicable activation gaps before receiving authorization to begin enrollment.

An SQV assesses whether a potential site has the resources and capabilities to conduct a proposed study. An SIV takes place later and focuses on training the selected site's team and reviewing readiness for a specific trial.

It helps research teams organize essential documents, staff training, facilities, equipment, study systems, and operational procedures before the initiation visit. It also helps identify outstanding requirements that could delay site activation.


 
 
 

Comments


bottom of page